Molecular mechanisms of cordycepin emphasizing its potential against neuroinflammation: An update

Govindula, Anusha; Pai, Anuja; Baghel, Saahil; Mudgal, Jayesh

doi:10.1016/j.ejphar.2021.174364

Cited by 15 publications

(5 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In order to conduct a systemic investigation of the possibility of developing CD as a potential therapeutic agent for TNBC, we first conducted in vitro experiments by treating two TNBC cell lines with different concentrations of CD and estimated its effects on cell growth, migration, and invasion. Consistent with the previous findings ( 19 ) about the anticancer and anti-metastatic activities of CD ( 2 , 3 , 6 , 7 , 20 ), we found that CD can not only inhibit growth but also repress both migration and invasion. We then took advantage of the 4T1 mouse allographic tumor model to substantiate the inhibitory effect of CD on breast cancer growth and metastasis in vivo .…”

Section: Discussionsupporting

confidence: 93%

“…More attention has been drawn to the scientists in basic research in the past few decades, and the major functional anticancer component in both C. sinensis and C. militaris is known as ‘Cordycepin’ (CD) (3′-deoxyadenosine), which is a derivative of the adenosine nucleotide differing from adenosine due to the absence of oxygen at the 3′-position of its ribose moiety ( 4 , 5 ). The underlying mechanisms of CD’s anticancer/antimetastatic activities include targeting various intracellular targets of nucleic acids (DNA/RNA) and proteins involved in cellular apoptosis, cell cycle, and other signaling pathways ( 2 , 6 – 8 ). The latest research also found the therapeutic potential of CD against COVID-19 virus or viral receptor as a novel therapeutic strategy ( 9 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cordycepin Inhibits Triple-Negative Breast Cancer Cell Migration and Invasion by Regulating EMT-TFs SLUG, TWIST1, SNAIL1, and ZEB1

Wei

Cheng

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Cancer metastasis is the most important cause of cancer-related death, and epithelial-to-mesenchymal transition (EMT) plays crucial roles in cancer metastasis. Cordycepin (CD) is highly enriched in the medicinally used Cordyceps mushroom. In this study, we conducted the antimetastatic activities of CD, specifically focusing on its regulatory effects on EMT-inducing transcription factors (EMT-TFs) in triple-negative breast cancer (TNBC). Our study showed CD to inhibit the growth, migration, and invasion of BT549 and 4T1 cancer cell lines, by employing cell viability assay and real-time cell analyses. The protein levels of N-Cadherin and E-Cadherin, as well as their transcription factors TWIST1, SLUG, SNAIL1, and ZEB1 in BT549 and 4T1 cells, were estimated by Western blot assays. Results from dual-luciferase reporter assays demonstrated that CD is capable of inactivating the EMT signaling pathway by inhibiting TWIST1 and SLUG expression. Furthermore, in vivo studies with mice carrying cancer cell-derived allograft tumors showed the inhibitory effect of CD on cancer cell growth and metastasis. Furthermore, the additive/synergistic anti-metastasis effect of CD and thymoquinone (TQ), another natural product with promising anticancer roles, was demonstrated by combinational treatment. The results from this research indicate that CD would be a promising therapeutic molecule against TNBC by targeting EMT-TFs, possibly in SLUG, TWIST1, SNAIL1, and ZEB1.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Introductionmentioning

confidence: 99%

Cordycepin Inhibits Triple-Negative Breast Cancer Cell Migration and Invasion by Regulating EMT-TFs SLUG, TWIST1, SNAIL1, and ZEB1

Wei

Cheng

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…To date, there are many reviews on cordycepin mainly focusing on the pharmacological action and its underlying mechanisms (Ashraf et al, 2020; Radhi et al, 2021; Sharma et al, 2022) or biological activity for aspects including anti‐inflammatory effects (Govindula et al, 2021; Tan et al, 2020), immune stimulation action (Das et al, 2021), anticancer efficacy (Chen et al, 2021; Khan & Tania, 2020; Nakamura et al, 2015; Tuli et al, 2013; Yoon et al, 2018) and function in reproduction (Chen et al, 2017). Besides, studies on the synthesis (Yang et al, 2020; Wang et al, 2022), production (Kontogiannatos et al, 2021), and enrichment (Kunhorm et al, 2019) of cordycepin have also been summarized.…”

Section: Introductionmentioning

confidence: 99%

Cordycepin: A review of strategies to improve the bioavailability and efficacy

Chen

Luo

Jiang

et al. 2023

Phytotherapy Research

View full text Add to dashboard Cite

Cordycepin is a bioactive compound extracted from Cordyceps militaris. As a natural antibiotic, cordycepin has a wide variety of pharmacological effects. Unfortunately, this highly effective natural antibiotic is proved to undergo rapid deamination by adenosine deaminase (ADA) in vivo and, as a consequence, its half‐life is shortened and bioavailability is decreased. Therefore, it is of critical importance to work out ways to slow down the deamination so as to increase its bioavailability and efficacy. This study reviews recent researches on a series of aspects of cordycepin such as the bioactive molecule's pharmacological action, metabolism and transformation as well as the underlying mechanism, pharmacokinetics and, particularly, the methods for reducing the degradation to improve the bioavailability and efficacy. It is drawn that there are three methods that can be applied to improve the bioavailability and efficacy: to co‐administrate an ADA inhibitor and cordycepin, to develop more effective derivatives via structural modification, and to apply new drug delivery systems. The new knowledge can help optimize the application of the highly potent natural antibiotic‐cordycepin and develop novel therapeutic strategies.

show abstract

“…So far, there are still no related effective drugs to cure AD patients. Notwithstanding that many drugs have been developed for treating central nervous system diseases, they have significant limitations, including severe side effects and complications (Govindula et al, 2021). Currently available treatments, based on early findings of cholinergic deficit, have only provided limited improvement in cognitive functions in AD.…”

Section: Introductionmentioning

confidence: 99%

Integration of network pharmacology and molecular docking to explore the molecular mechanism of Cordycepin in the treatment of Alzheimer’s disease

Zhao

Yang

et al. 2022

Front. Aging Neurosci.

View full text Add to dashboard Cite

BackgroundCordycepin is a nucleoside adenosine analog and an active ingredient isolated from the liquid fermentation of Cordyceps. This study sought to explore the mechanism underlying the therapeutic effect of Cordycepin against Alzheimer’s disease using network pharmacology and molecular docking technology.MethodsTCMSP, SYMMAP, CTD, Super-pred, SEA, GeneCards, DisGeNET database, and STRING platform were used to screen and construct the target and protein interaction network of Cordycepin for Alzheimer’s disease. The results of Gene Ontology annotation and KEGG pathway enrichment analysis were obtained based on the DAVID database. The Omicshare database was also applied in GO and KEGG pathway enrichment analysis of the key targets. The protein–protein interaction network was constructed using the STRING database, and the potential effective targets for AD were screened based on the degree values. The correlation between the potential targets of Cordycepin in the treatment of AD and APP, MAPT, and PSEN2 was analyzed using (GEPIA) databases. We obtained potential targets related to aging using the Aging Altas database. Molecular docking analysis was performed by AutoDock Vina and Pymol software. Finally, we validated the significant therapeutic targets in the Gene Expression Omnibus (GEO) database.ResultsA total of 74 potential targets of Cordycepin for treating Alzheimer’s disease were identified. The potential targets of Cordycepin for the treatment of AD mainly focused on Lipid and atherosclerosis (hsa05417), Platinum drug resistance (hsa01524), Apoptosis (hsa04210), and Pathways in cancer (hsa05200). Our findings suggest that the therapeutic effect of Cordycepin on AD is primarily associated with these biological processes. We obtained 12 potential therapeutic targets for AD using the degree value in Cytoscape. Interestingly, AKT1, MAPK8, BCL2L1, FOXO3, and CTNNB1 were not only significantly associated with pathogenic genes (APP, MAPT, and PSEN2) but also with longevity in Alzheimer’s Disease. Thus we speculated that the five target genes were potential core targets mediating the therapeutic effect of Cordycepin against AD. Moreover, molecular docking results analysis showed good binding affinity between Cordycepin and the five core targets. Overall, MAPK8, FOXO3 and CTNNB1 may have significant clinical and treatment implications.ConclusionNetwork pharmacology demonstrated that Cordycepin exerts a therapeutic effect against Alzheimer’s disease via multiple targets and signaling pathways and has huge prospects for application in treating neurodegenerative diseases.

show abstract

Molecular mechanisms of cordycepin emphasizing its potential against neuroinflammation: An update

Cited by 15 publications

References 75 publications

Cordycepin Inhibits Triple-Negative Breast Cancer Cell Migration and Invasion by Regulating EMT-TFs SLUG, TWIST1, SNAIL1, and ZEB1

Cordycepin Inhibits Triple-Negative Breast Cancer Cell Migration and Invasion by Regulating EMT-TFs SLUG, TWIST1, SNAIL1, and ZEB1

Cordycepin: A review of strategies to improve the bioavailability and efficacy

Integration of network pharmacology and molecular docking to explore the molecular mechanism of Cordycepin in the treatment of Alzheimer’s disease

Contact Info

Product

Resources

About